Join to View Full Profile
450 Brookline AveBoston, MA 02215
Phone+1 617-632-3090
Fax+1 617-632-4448
Dr. Hanna is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2014 - 2016
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2011 - 2014
Mass General Brigham/Massachusetts Eye and Ear/Harvard Medical SchoolInternship, Otolaryngology - Head and Neck Surgery, 2010 - 2011
Georgetown University School of MedicineClass of 2010
Certifications & Licensure
MA State Medical License 2012 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia Start of enrollment: 2018 Dec 05
- A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma Start of enrollment: 2019 Aug 05
- Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas Start of enrollment: 2020 Dec 24
- Join now to see all
Publications & Presentations
PubMed
- Safety and efficacy of a selective inhibitor of cyclin-dependent kinase 9 (KB-0742) in patients with recurrent or metastatic adenoid cystic carcinoma.Glenn J Hanna, Gregory M Cote, Rashmi Chugh, Jacob S Thomas, Jyoti Malhotra
Cancer Research Communications. 2025-04-25 - Corrigendum to "PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S." [Oral Oncol. 161 (2025) 107146].Glenn J Hanna, Dandan Zheng, Wei Gao, Gleicy M Hair, Lei Ai
Oral Oncology. 2025-04-11 - Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck.Jia Luo, Justin A Bishop, Steven G DuBois, Glenn J Hanna, Lynette M Sholl
Nature Reviews. Clinical Oncology. 2025-04-01
Journal Articles
- Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Untreated Oral Cavity Squamous Cell CarcinomaGlenn J Hanna, Nicole Chau, Jochen Lorch, Robert I Haddad, JAMA Oncology
- Genomic Correlates of Response to Immune Checkpoint Blockade in Microsatellite-Stable Solid TumorsJeffrey A Engelman, David A Barbie, Nicole G Chau, Glenn J Hanna, Natalie I Vokes, Sabina Signoretti, Pasi A Janne, Robert I Haddad, Lynette M Sholl, Rizwan Haq, Peter..., Nature
- CIC‐NUTM1 Fusion: A Case Which Expands the Spectrum of NUT‐Rearranged Epithelioid MalignanciesGlenn J Hanna, Christopher A French, Genes, Chromosomes and Cancer
Authored Content
- Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Untreated Oral Cavity Squamous Cell CarcinomaAugust 2020
Press Mentions
Dana-Farber Experts Present Innovative Cancer Studies at the 2025 AACR Annual MeetingApril 26th, 2025- Dana-Farber Research Highlights Head and Neck, Breast, Lung, and Survivorship Studies at AACR Annual Meeting 2025April 25th, 2025
- “Eye-Opening” Data Raise Concerns About Off-Label Immunotherapy Use in Head and Neck CancerMarch 24th, 2025
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
